
A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.

A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.

A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).

November 8th 2017